Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #5473
Reference
Name
Medicines related to valproate: risk of abnormal pregnancy outcomes
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY
DRUG THERAPY
PHARMACEUTICAL SERVICES
Description
Informs of important new information and strengthened warnings related to safety of medicines related to valproate (sodium valproate, valproic acid [brand leader: Epilim] and valproate semisodium [brand leader: Depakote]), following completion of a Europe-wide review.
Contact Name
John Hannah
Contact Email
Contact Address
Scottish Government Directorate General Health & Social Care, Directorate of Health Quality and Strategy, Pharmacy & Medicines Division, Medicines Branch, St Andrew's House Regent Road, Edinburgh EH1 3DG
Contact Phone
Created
2015-01-21 00:00:00
Click to go back to homepage